Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
Join this webinar to hear about the latest RMM technology and how it aligns with UPS testing criteria.
article

Bioprocessing & Bioproduction In-Depth Focus 2021

Featured in this in-depth focus, articles exploring why cleanroom infrastructure must transform to meet the needs of the cell and gene therapy industry and discussing a novel platform for discovering and developing genetically-targeted therapies for autoimmune diseases.

Bioprocessing & Bioproductoion

    To read this in-depth focus in full, please complete the form below:

     









    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    • Cleanroom infrastructure innovation to fulfil the needs of cell and gene therapies
      Biopharmaceuticals have transformed the patient care landscape, but alongside this step change in treatment capability comes the need for a similar paradigm shift in manufacturing capability. Here, Maik W Jornitz, President & CEO of G-CON Manufacturing Inc. highlights how cleanroom infrastructure must develop to keep pace with ever evolving industry needs.
    • A new small molecule drug discovery and development platform for HLA-associated autoimmune diseases
      In the arsenal of approved small molecule drugs, effective, genetically-targeted therapies for the treatment of autoimmune diseases are conspicuously scarce. ImmunoMolecular Therapeutics (IM Therapeutics) has developed a paradigm for the discovery and development of new molecular entities as a broad platform for blocking genetic targets that confer risk of disease development and are key to triggering autoimmune responses. Ryan J Schutte and Robert B Perni explain more.